Education
About Us
Working with TipRanks
Follow Us
Kenvue, Inc. (KVUE)
NYSE:KVUE
KVUE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$17.85 - $25.17
Previous CloseN/A
Volume2.33M
Average Volume (3M)19.41M
Market Cap
$42.24B
Enterprise Value$49.57B
Total Cash (Recent Filing)$1.06B
Total Debt (Recent Filing)$8.74B
Price to Earnings (P/E)40.1
Beta0.31
Next Earnings
Oct 23, 2025EPS EstimateN/A
Last Dividend Ex-Date
May 14, 2025Dividend Yield3.73%
Share Statistics
EPS (TTM)0.21
Shares Outstanding1,919,909,900
10 Day Avg. Volume20,789,839
30 Day Avg. Volume19,411,602
Financial Highlights & Ratios
PEG Ratio10.48
Price to Book (P/B)4.15
Price to Sales (P/S)0.00
P/FCF Ratio28.89
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue0.80
Enterprise Value/Gross Profit5.59
Enterprise Value/Ebitda3.83
Forecast
1Y Price Target
$24.55Price Target Upside11.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Kenvue, Inc. News
Bulls Say, Bears Say
Bulls Say
Leadership ChangeThe appointment of Mr. Kirk Perry as interim CEO indicates a commitment to conducting a comprehensive search for the company’s next permanent CEO, following the replacement of both the CEO and CFO.
Portfolio OptimizationReview of strategic alternatives announced by KVUE could lead to portfolio simplification, which may enhance operating performance to accelerate profitable growth.
Strategic ReviewThe announced CEO transition and review of strategic alternatives should be well received, given mostly disappointing results and a number of execution challenges since the company’s IPO in 2023.
Bears Say
Financial PerformancePreliminary 2Q25 results indicating OSG -4.2% suggest that patience has worn out due to disappointing performance.
Sales PerformancePreliminary Q2 sales and earnings results were below expectations, with organic sales at -4.2% compared to the Street’s -1% prior.
Skin Health & Beauty SegmentThe skin health & beauty segment shows signs of weakness, with weak volumes likely to persist due to soft sales in sun care and greater pricing investments.
Ownership Overview
1.12% Insiders
35.61% Mutual Funds
0.88% Other Institutional Investors
33.99% Public Companies and Individual Investors
KVUE FAQ
What was Kenvue, Inc.’s price range in the past 12 months?
Kenvue, Inc. lowest stock price was $17.85 and its highest was $25.17 in the past 12 months.
What is Kenvue, Inc.’s market cap?
Kenvue, Inc.’s market cap is $42.24B.
When is Kenvue, Inc.’s upcoming earnings report date?
Kenvue, Inc.’s upcoming earnings report date is Oct 23, 2025 which is in 94 days.
How were Kenvue, Inc.’s earnings last quarter?
Kenvue, Inc. released its earnings results on Jul 14, 2025. The company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.282 by -$0.072.
Is Kenvue, Inc. overvalued?
According to Wall Street analysts Kenvue, Inc.’s price is currently Undervalued.
Does Kenvue, Inc. pay dividends?
Kenvue, Inc. pays a Quarterly dividend of $0.205 which represents an annual dividend yield of 3.73%. See more information on Kenvue, Inc. dividends here
What is Kenvue, Inc.’s EPS estimate?
Kenvue, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kenvue, Inc. have?
Kenvue, Inc. has 1,919,909,900 shares outstanding.
What happened to Kenvue, Inc.’s price movement after its last earnings report?
Kenvue, Inc. reported an EPS of $0.21 in its last earnings report, missing expectations of $0.282. Following the earnings report the stock price went up 2.249%.
Which hedge fund is a major shareholder of Kenvue, Inc.?
Currently, no hedge funds are holding shares in KVUE
Kenvue, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.55 (11.59% Upside)
$24.55 (11.59% Upside)
Blogger Sentiment
Bullish
KVUE Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 8.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.60%
12-Months-Change
Fundamentals
Return on Equity
10.22%
Trailing 12-Months
Asset Growth
-3.76%
Trailing 12-Months
Company Description
Kenvue, Inc.
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
KVUE Company Deck
KVUE Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook for Kenvue, with strong execution of strategic plans and market share gains in certain segments overshadowed by organic sales declines and challenges in the Skin Health and Beauty segment. The impact of tariffs and foreign exchange rates also posed significant challenges.Read More>KVUE Revenue Breakdown
42.23% Self Care
30.33% Essential Health
27.43% Skin Health and Beauty
KVUE Stock 12 Month Forecast
Average Price Target
$24.55
▲(11.59%Upside)